Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.
2 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
-
Natera
company in San Carlos, United States
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval expands patient access to therapies for ACCORD.
- Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- FDA approved a drug based on UVA research led by Xuemei Huang.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaNatera pursues ctDNA assay approval after Phase III victory Natera’s Signatera assay has been found to accurately predict if a patient with muscle-invasive bladder cancer (MIBC) will benefit from adj
- Business WireIMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit Topline results from the trial show that Signatera-positive patients trea